Alfonso Monge, MD
Internal Medicine · Miami, FLNPI 1720057987
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$785
- AstraZeneca$558
- Amgen$543
- GSK$509
- Novo Nordisk$493
- Pfizer$489
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,802100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 51 | $785 |
| AstraZeneca | 30 | $558 |
| Amgen(2 entities) | 35 | $543 |
| GSK | 26 | $509 |
| Novo Nordisk | 29 | $493 |
| Pfizer | 30 | $489 |
| Abbott | 24 | $477 |
| AbbVie(2 entities) | 19 | $383 |
| Exact Sciences | 12 | $284 |
| Sanofi-aventis U.S. LLC | 8 | $148 |
| Novartis | 8 | $126 |
| Dexcom, Inc. | 7 | $125 |
| Amarin Pharma, Inc. | 5 | $88 |
| Merck | 5 | $80 |
| Johnson & Johnson | 4 | $74 |
| Astellas Pharma US Inc | 4 | $70 |
| Sanofi Pasteur Inc. | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Boehringer Ingelheim | 3 | $51 |
| Saluda Medical Americas, Inc. | 2 | $49 |
| Inspire Medical Systems, Inc. | 1 | $40 |
| Lifescan, Inc. | 2 | $34 |
| Medtronic | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Edwards Lifesciences | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Bayer | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Philips North America LLC | 1 | $14 |
How this compares
$5,802 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $121,890 |
| OzempicSemaglutide | 56 | $67,581 |
| MounjaroTirzepatide | 38 | $40,322 |
| JardianceEmpagliflozin | 34 | $37,048 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $36,773 |
| FarxigaDapagliflozin Propanediol | 39 | $32,692 |
| XareltoRivaroxaban | 22 | $21,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,402 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $12,891 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,184 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $9,353 |
| Atorvastatin Calcium | 862 | $8,163 |
| Levothyroxine Sodium | 354 | $5,531 |
| SynthroidLevothyroxine Sodium | 55 | $5,069 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $4,906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $489 | $121,890107 claims |
| Novo NordiskOzempic | $493 | $67,58156 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $51 | $47,23153 claims |
| Lilly USA, LLCMounjaro | $785 | $40,32238 claims |
| AstraZenecaFarxiga, Symbicort | $558 | $37,17552 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $509 | $28,75642 claims |
| Johnson & JohnsonXarelto | $74 | $21,75822 claims |
| AbbVieSynthroid | $383 | $5,06955 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.